NCT00887809 · REGISTRY CONDITION SEARCH

Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2016-01-25

The purpose of this study is to test whether an experimental drug called bevacizumab given together with gemcitabine and docetaxel, a standard chemotherapy regimen for sarcoma, can help sarcoma patients. This trial will examine what effects, good and/or bad the combination of gemcitabine, docetaxel and bevacizumab has on sarcoma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Objective Response

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Histologically confirmed unresectable metastatic or locally recurrent leiomyosarcoma, Malignant Fibrous Histiocytoma (MFH, also known as high grade Undifferentiated Pleomorphic Sarcoma) pleomorphic liposarcoma, rhabdomyosarcoma or angiosarcoma. * Zero to one prior chemotherapy regimens for metastatic disease. Prior adjuvant therapy will not count provided it was more than one year previously. * Measurable disease as defined by RECIST * Adequate performance status - ECOG 0 or 1 * Patients must be recovered from the toxic effects of prior chemotherapy or radiation. Therapy may not start until at least 3 weeks since prior cytotoxic chemotherapy, two weeks from completion of radiation therapy, and one week for patients on tyrosine kinase inhibitors or other targeted therapy. * Age 18 To 75. As it is quite difficult to administer high dose docetaxel with gemcitabine, to the elderly, in order to protect patient safety, we will restrict eligibility to patients between the ages of 18 and 75. * Adequate hematologic, hepatic and renal function as defined below * Hemoglobin \> or = to 8.0 g/dl * Absolute neutrophil count \> or = to 1,500/mm3 * Platelet count \> or = to 100,000/mm3 * Total Bilirubin \< or = to1.5 x upper limit of normal (ULN). * ALT (SGOT) or AST (SGPT) \< or = to 5 x ULN. * Alkaline Phosphatase \< or = to 2.5 x ULN or ≤ 5 x ULN in presence of liver metastases. * Serum creatinine 2.0 mg/dL * Ability to understand informed consent and comply with treatment protocol * Normal cardiac ejection fraction * Urine protein:creatinine (UPC) ratio \< than or = to 1.0 at screening Exclusion Criteria: * Uncontrolled intercurrent illness including infection or congestive heart failure within 6 months. * Prior therapy with gemcitabine, docetaxel or bevacizumab * Patients receiving other investigational agents * Patients with known brain metastases * Pregnancy or unwillingness to use effective birth control * Patients with HIV disease will be permitted, only if they are on effective anti-retroviral therapy, have a CD4 count greater than 400, and have had no opportunistic infections within the past 6 months. * Patients on anti-coagulation will be permitted if they are on a stable dose of warfarin or low-molecular weight heparin, and have had no major bleeds within the past 6 months. * Inability to comply with study and/or follow-up procedures. * Life expectancy of less than 12 weeks. * Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study * Active malignancy, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix within last three years * Inadequately controlled hypertension (defined as systolic blood pressure \> 150 and/or diastolic blood pressure \> 100 mmHg lasting \> 24 hours on antihypertensive medications) * Any prior history of hypertensive crisis or hypertensive encephalopathy * New York Heart Association (NYHA) Grade II or greater congestive heart failure * Significant vascular disease (e.g., aortic aneurysm, aortic dissection), requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1 * Symptomatic peripheral vascular disease * Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment * Serious, non-healing wound, active ulcer, or non-healing bone fracture * Proteinuria at screening as demonstrated by * Urine protein:creatinine (UPC) ratio \> or = to 1.0 at screening (patients discovered to have UPC ratio \> or = to 1.0 at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible). * Known hypersensitivity to any component of bevacizumab * Pregnant (positive pregnancy test) or lactating. Use of effective means of contraception (men and women) in subjects of child-bearing potential * History of hemoptysis (bright red blood of 1/2 teaspoon or more per episode) within 3 months prior to study enrollment. * Any history of stroke or transient ischemic attack within 6 months * History of myocardial infarction or unstable angina within 6 months
healthy Volunteers: false
maximum Age: 75 Years
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients will receive bevacizumab at 15 mg/kg on day 1 of each 21-day cycle intravenously over 30 minutes followed by a one hour (+30/-15 min) break. For cycles 1 through 6, gemcitabine will be administered at 900 mg/m2 over 90 minutes on day 1 and 8 of a 21-day cycle. Docetaxel will be administered at 75 mg/m2, over 60 minutes, on day 8. This will be followed by either 5 days of filgrastim or a single injection of pegfilgrastim. For cycles 7 and beyond, gemcitabine will be given at 800 mg/m2 over 30 minutes on day 1 and 8; docetaxel will be given at 35 mg/m2 over 30 minutes, also on days 1 and 8.
intervention Names
Drug: gemcitabine
Drug: docetaxel
Drug: bevacizumab
label
gemcitabine and docetaxel with bevacizumab
type
EXPERIMENTAL

interventions

arm Group Labels
gemcitabine and docetaxel with bevacizumab
name
gemcitabine
type
DRUG
arm Group Labels
gemcitabine and docetaxel with bevacizumab
name
docetaxel
type
DRUG
arm Group Labels
gemcitabine and docetaxel with bevacizumab
name
bevacizumab
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 47
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Overall Objective Response will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)
measure
Overall Objective Response
time Frame
6 months

Full study description

brief Summary: The purpose of this study is to test whether an experimental drug called bevacizumab given together with gemcitabine and docetaxel, a standard chemotherapy regimen for sarcoma, can help sarcoma patients. This trial will examine what effects, good and/or bad the combination of gemcitabine, docetaxel and bevacizumab has on sarcoma.

Source references